Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1577261

This article is part of the Research TopicImmunotherapy Resistance in Solid Tumor: Intrinsic Characteristics of Cancer Cells and Tissue Microenvironment FactorsView all articles

Bibliometric Analysis of RNA-Binding Proteins in Osteosarcoma: Unraveling Research Trends and Hotspots

Provisionally accepted
  • 1Department of Health Science Center, Ningbo University, Ningbo, Zhejiang, China
  • 2Department of Hand Surgery, Ningbo No.6 Hospital, Ningbo, China
  • 3department of neurosurgery, neurosurgery, shaoxing people's hospital, shaoxing, China

The final, formatted version of the article will be published soon.

Background: RNA-binding proteins (RBPs), a class of molecules that play a crucial role in regulating gene expression, have attracted considerable attention in cancer biology research. RBPs influence osteosarcoma progression by modulating RNA metabolism and participating in cellular proliferation, differentiation, apoptosis, and interactions within the tumor microenvironment. Understanding the current status and future trends of RBPs is crucial for the advancement of osteosarcoma research. Methods: Relevant literature was sourced from the Web of Science, PubMed, and Scopus databases covering the period from January 1, 1994, to December 31, 2024. Using professional analytical tools such as R bibliometrix, VOSviewer, CiteSpace, and SCImago, we conducted a multidimensional visual analysis of publication trends, contributions from countries and institutions, influential authors, significant publications, and keyword distribution. Results: Research on RBPs in osteosarcoma began in 1994, with a notable increase in published studies since 2016. The leading countries for research output were China and the United States, primarily from three major U.S. institutions: the University of Illinois, Harvard University, and UT MD Anderson Cancer Center. Significant contributors to this field included Kannanganattu V. Prasanth, Jean-Yves Masson, Yang Wang. The most cited article was a review titled The potential role of RNA N6-methyladenosine in Cancer progression by Professor Shaoqing Ju from China (2020). Prominent journals within this domain included Cancer Research (USA), Oncogene (England), Cancer Cell International (England), and the Journal of Bone and Mineral Research (USA). Conclusion: This study highlights the critical role of RBPs in osteosarcoma. We conducted a systematic literature review using bibliometric methods to outline the research landscape, identify hotspots and emerging trends, and provide valuable references for future studies. Future research should focus on enhancing international collaboration, exploring molecular mechanisms, and connecting these insights to clinical applications—especially in targeted drug development—to improve treatment outcomes for osteosarcoma patients.

Keywords: Osteosarcoma, RNA-Binding Protein, Bibliometric, non-coding RNA, bone tumor

Received: 15 Feb 2025; Accepted: 01 Sep 2025.

Copyright: © 2025 Gu, Zhang, Hu, Xu, Wang, Ruan, Qian, Ma and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Hong Chen, Department of Hand Surgery, Ningbo No.6 Hospital, Ningbo, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.